635 KEYNOTE-495/KeyImPaCT: updated analysis of a biomarker-directed, randomized, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer

MLA

Roy Herbst, et al. “635 KEYNOTE-495/KeyImPaCT: Updated Analysis of a Biomarker-Directed, Randomized, Phase 2 Trial of Pembrolizumab-Based Combination Therapy for Non-Small Cell Lung Cancer.” Regular and Young Investigator Award Abstracts, Nov. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........6914afa9aeac906b9e5e9ce6d58ce264&authtype=sso&custid=ns315887.

APA

Roy Herbst, Wei-Sen Lam, Matthew Hellmann, Matthew Gubens, Charu Aggarwal, Daniel Shao Weng Tan, Enriqueta Felip, Joanne Chiu, Jong-Seok Lee, James Chih-Hsin Yang, Edward Garon, Giovanna Finocchiaro, Myung-Ju Ahn, Alexander Luft, Gregory Landers, Andrea Basso, Hua Ma, Julie Kobie, John Palcza, … Martin Gutierrez. (2022). 635 KEYNOTE-495/KeyImPaCT: updated analysis of a biomarker-directed, randomized, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer. Regular and Young Investigator Award Abstracts.

Chicago

Roy Herbst, Wei-Sen Lam, Matthew Hellmann, Matthew Gubens, Charu Aggarwal, Daniel Shao Weng Tan, Enriqueta Felip, et al. 2022. “635 KEYNOTE-495/KeyImPaCT: Updated Analysis of a Biomarker-Directed, Randomized, Phase 2 Trial of Pembrolizumab-Based Combination Therapy for Non-Small Cell Lung Cancer.” Regular and Young Investigator Award Abstracts, November. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........6914afa9aeac906b9e5e9ce6d58ce264&authtype=sso&custid=ns315887.